Hyderabad-based drugmaker Laurus Labs announced its results for the second quarter of 2026-27 (July–September) on Thursday. The company's registered office is in Anakapalli district, Andhra Pradesh.
The numbers
- Net profit ₹441 crore, against ₹195 crore a year ago (up about 126%).
- Revenue ₹2,206 crore, against ₹1,653 crore (up 33%).
- EBITDA ₹762 crore (up 78%), a 34.5% margin.
- First-quarter profit was ₹368 crore, so Q2 is about 20% higher.
- CDMO (contract manufacturing) revenue was ₹904 crore, up 75%, according to Elets eHealth.
New investments
Laurus agreed to buy 60% of Montreal-based Galenvs Sciences, which works on oligonucleotides and magnetic nanoparticles. Free Press Journal reports it is also taking a 52% stake in SI&C Resins, a peptide-resin technology firm. The company has started its first commercial-scale peptide plant in Visakhapatnam.
"Laurus achieved another record quarter of strong growth in revenue and profits," said CEO Dr Satyanarayana Chava. He said the company is expanding peptide capacity to meet surging demand for peptide therapeutics.
